|AHFS/Drugs.com||International Drug Names|
|Chemical and physical data|
|Molar mass||385.370 g/mol|
|3D model (JSmol)|
|(what is this?)|
Pathohistochemical studies have revealed that the volume of the infarction in the middle cerebral artery occlusion model could be decreased by nilvadipine.
Following this study, an international research consortium led by Trinity College Dublin (Ireland) in May 2011 announced the selection for funding of a large-scale European clinical trial of nilvadipine. More than 500 Alzheimer’s patients will participate in the multicenter phase III clinical trial designed to study the effectiveness of nilvadipine.
|This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it.|